WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522540
CAS#: 245063-59-6
Description: NS-1209 is an antiepileptic drug candidate currently under clinical trials. Epilepsy is one of the most common serious neurological disorders in adults, affecting approximately 50 million people worldwide at a total annual cost, in Europe, of approximately 15.5 billion Euros.
MedKoo Cat#: 522540
Name: NS-1209
CAS#: 245063-59-6
Chemical Formula: C24H28N4O7S
Exact Mass: 516.1679
Molecular Weight: 516.57
Elemental Analysis: C, 55.80; H, 5.46; N, 10.85; O, 21.68; S, 6.21
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: NS-1209; NS 1209; NS1209; 245063-59-6; SPD-502; SPD502; SPD 502
IUPAC/Chemical Name: (R,Z)-2-(((5-(4-(N,N-dimethylsulfamoyl)phenyl)-8-methyl-2-oxo-1,2,6,7,8,9-hexahydro-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene)amino)oxy)-4-hydroxybutanoic acid
InChi Key: CFJRSKULEDUDKL-HXUWFJFHSA-N
InChi Code: InChI=1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)/t20-/m1/s1
SMILES Code: O=C(O)[C@H](O/N=C1C2=C(C(C3)=C(CCN3C)C(C4=CC=C(C=C4)S(N(C)C)(=O)=O)=C2)NC/1=O)CCO
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 516.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Mula M. Emerging drugs for focal epilepsy. Expert Opin Emerg Drugs. 2013 Mar;18(1):87-95. doi: 10.1517/14728214.2013.750294. Epub 2012 Nov 26. Review. PubMed PMID: 23176519.
2: Perucca E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia. 2009 Dec;50 Suppl 12:49-50. doi: 10.1111/j.1528-1167.2009.02366.x. Review. PubMed PMID: 19941524.
3: Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem. 2008 Feb 14;2:21-39. PubMed PMID: 19787095; PubMed Central PMCID: PMC2746576.
4: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PubMed PMID: 15071612.
